Cancer
New breast cancer guidelines poised to revolutionise breast cancer care in China
The 2024 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) has published new guidelines that integrate cutting-edge international research with Chinese clinical evidence – including highlighting the crucial role of targeted therapies for HER2-positive breast cancer.
The guidelines also emphasise the growing impact of immunotherapy in triple-negative breast cancer (TNBC), and outline the strategic use of CDK4/6 inhibitors for HR-positive cases.
Additionally, they introduce a groundbreaking approach to HER2 low-expression breast cancer, establishing a new paradigm for personalised treatment in China.
Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.
The continuous development of new therapies, combined with the pressing need to personalise treatments for diverse patient populations, underscores the importance of evidence-based guidelines that blend global innovations with local healthcare needs.
This challenge calls for guidelines that not only reflect international advancements but also take into account the clinical realities and accessibility within specific regions, particularly in China.
The 2024 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines represent a pioneering effort by a team from Fifth Medical Center of PLA General Hospital and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences, to provide updated, region-specific treatment recommendations.
These guidelines offer a comprehensive approach to managing breast cancer, informed by both high-quality clinical studies and real-world data from China, ensuring that the treatment strategies are both globally relevant and locally applicable.
The updated guidelines place a strong emphasis on precision medicine, offering tailored treatment approaches for various subtypes of breast cancer.
For HER2-positive cancers, the guidelines advocate for dual-target therapies such as trastuzumab and pertuzumab, along with the introduction of pyrotinib in combination with trastuzumab as a novel regimen. This new combination is supported by data from the PHEDRA study, which showed significant improvements in pathologic complete response rates.
In triple-negative breast cancer (TNBC), the guidelines highlight the importance of immunotherapy, referencing the TORCHLIGHT study which demonstrated enhanced progression-free and overall survival with the addition of toripalimab to nab-paclitaxel.
Notably, the guidelines also address HER2 low-expression breast cancer, recommending a personalised treatment approach based on hormone receptor status and previous treatments, including the use of antibody-drug conjugates (ADCs), or targeted therapies after ADC failure. These advancements reflect a broader global trend towards precision oncology, aiming to optimise treatment effectiveness based on individual tumour characteristics.
Dr.Zefei Jiang, principal author of the 2024 CSCO BC guidelines, emphasises the transformative potential of these updates: “The 2024 guidelines are a reflection of the powerful synergy between global research advancements and clinical insights from China.
“By integrating these perspectives, we ensure that our recommendations are not only at the cutting edge of scientific innovation but are also grounded in the practical realities of our healthcare system. Our goal is to create a balanced framework that aligns international standards with the unique needs of Chinese patients, ultimately enhancing care and improving outcomes.”
The 2024 CSCO BC guidelines are poised to revolutionize breast cancer care in China, with the potential to significantly improve patient outcomes and reduce treatment disparities.
By prioritising the generation of local evidence, these guidelines pave the way for more personalised treatment protocols tailored to the specific genetic and clinical profiles of Chinese patients. This approach promises not only to benefit China’s domestic patient population but also to contribute valuable data to the global oncology community, enriching international discussions on breast cancer management.
The broader implications of these guidelines are profound, as they aim to narrow gaps in treatment efficacy and create a more equitable landscape in the global fight against breast cancer.
Insight
AI cuts interval breast cancers in Swedish trial
Insight
Study links changing population to low London screening rates
London’s shifting population is holding down breast screening uptake, experts have said, with the capital at 62.8 per cent in 2024, below the NHS’s acceptable 70 per cent threshold.
The London Assembly Health Committee recently heard that the capital faces distinct challenges compared with the rest of the country and that these issues must be addressed.
Josephine Ruwende, a cancer screening lead at NHS England, said frequent moves within the rented sector and the cost-of-living crisis pushing people out of London had made it difficult to reach eligible patients, which she described as “population churn”.
She said: “This is people changing addresses and then not updating their GP, this then affects the invitation process because GP details are used to identify individuals who are eligible.
“In boroughs where we have the highest population churn, we see it strongly associated with lower uptake.”
She noted that even in the wealthiest boroughs there can be high levels of movement, with around 40 per cent of residents changing address within a year.
Such areas also tend to have more people who own second homes or spend long periods abroad, making it harder for the NHS to keep contact details up to date.
As a result, screening invitations may be sent to out-of-date addresses or to people who are overseas.
Leeane Graham, advocacy lead at Black Women Rising, which supports women of colour with a cancer diagnosis, said there were cultural barriers, fear and a mistrust of the health service due to previous experience within communities.
She said: “If you’ve never been for a breast screening before, the thought of having a mammogram can be really, really terrifying.”
Helen Dickens, from Breast Cancer Now, said other reasons included a lack of understanding of breast screening, along with concerns about discomfort, trust and practical issues such as travel.
She said: “We have amazing public transport and we feel that we’ve got great accessibility, but we also know that we don’t have screening centres in every borough.
“We know that for some women that barrier of transport and access will still be a really big reason why they’re not attending screenings.”
NHS London launched its first screening campaign last year in response to the figures, aiming to increase detection at an earlier stage.
Insight
Period blood screening could boost cervical cancer checks
Testing period blood for signs of cervical cancer could offer an accurate, convenient screening option for women who avoid clinic appointments, researchers say.
The current NHS test involves a nurse or doctor taking cells from the cervix, yet a third of those invited do not attend.
A study of the new test, which can be done at home, used blood collected on a cotton strip attached to a standard sanitary pad.
In research involving more than 3,000 women aged 20 to 54 years, Chinese investigators compared testing period blood collected on mini-pads with samples taken by clinicians.
Results were shared via a dedicated app.
When analysed in the lab, blood testing was nearly as good at identifying people with disease as other methods, and very good at ruling out those without it.
Cervical screening appointments are offered to all women, and anyone with a cervix, every five years between ages 25 and 64 in the UK.
Screening looks for high-risk human papillomavirus, a virus that can cause cancer.
A nurse or doctor carries out the test using a speculum to access the cervix.
However, five million women are not up to date, for reasons including fear, pain and discomfort.
“Cervical screening can be difficult for some women for many reasons, like if they have had a bad previous experience, they are menopausal, they have a physical or learning disability, cultural barriers, or are a survivor of sexual violence,” said Athena Lamnisos from charity The Eve Appeal.
Younger women, those with disabilities, and people from ethnic minority communities and LGBT+ groups are more likely to miss appointments.
Researchers say using menstrual blood for HPV testing is convenient, respects privacy and reduces discomfort.
Anyone who tests positive for HPV would be sent for a colposcopy, a close examination of the cervix with a magnifying instrument to look for pre-cancerous cells.
Experts caution that period blood tests are not an immediate alternative to current screening because only women who menstruate could use them.
Some also note the study may have overestimated performance because not all participants had a biopsy to double check results.
Sophie Brooks, health information manager at Cancer Research UK, said it was encouraging to see research exploring new ways to make screening more accessible.
She said testing menstrual blood for HPV was an interesting, non-invasive approach but more research in diverse groups is needed to see how it could fit into existing programmes.
Athena Lamnisos added that it was exciting to see more acceptable ways of offering a potentially life-saving test.
“People have different barriers and concerns about screening, so being able to offer a choice of different methods could be very positive for some who are eligible for screening but don’t currently attend,” she said.
The NHS is already sending at-home test kits to women in some areas of England who have missed several screening appointments.
These DIY kits, containing a vaginal swab, will be sent out more widely at some point this year.
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Hormonal health4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight3 weeks agoChina’s birth rate hits record low despite government fertility efforts






